Last reviewed · How we verify
AT01
AT01 is a small molecule that targets the SGLT2 receptor.
AT01 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | AT01 |
|---|---|
| Also known as | DHP-101 |
| Sponsor | Dhp Korea Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, AT01 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful for the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load (PHASE1)
- Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis (PHASE2)
- Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis (PHASE3)
- The Impact of Treadmills and Cooler Environments for Office Workplaces on Ergonomics, Heating Energy Requirements, Performance, as Well as Back and Cardiometabolic Health (NA)
- A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis (PHASE2)
- Comparing the Efficacy of Earplugs and Eye Masks on Pain and Sleep Quality (NA)
- Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AT01 CI brief — competitive landscape report
- AT01 updates RSS · CI watch RSS
- Dhp Korea Co., Ltd. portfolio CI